Clinical Trial

A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CAR NK cells in patients with relapsed/refractory B-cell related autoimmune diseases.15 patients are planned to be enrolled in the dose-escalation trial . The primary objective of the study is to evaluation of the safety and feasibility of CAR NK cells for the treatment of relapsed/refractory B-cell related autoimmune diseases. The secondary objective is to evaluate the effectiveness of CAR NK cells for the treatment of relapsed/refractory B-cell related autoimmune diseases. The exploratory objective is to evaluate expansion, persistence and ability to deplete B cells of CAR NK cells in patients with relapsed/refractory B-cell related autoimmune diseases.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-03-13 -> 2026-12-13 2026-08-12
Trial Details
NCT Number NCT06318533
Lead Sponsor YANRU WANG
Collaborators: Rui Therapeutics Co., Ltd
Conditions Autoimmune Diseases
Enrollment 15 participants
Start Date 2024-03-13
Primary Completion 2026-12-13 (estimated)
Study Completion 2027-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-13